Elraglusib is under clinical development by Actuate Therapeutics and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Elraglusib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Elraglusib overview
9-ING41 is under development for the treatment of solid tumors including primary myelofibrosis, post-polycythemia vera myelofibrosis (PPV-MF), salivary gland cancer, adenoid cystic carcinoma (ACC), post-essential thrombocythemia myelofibrosis (Post-ET MF), metastatic pancreatic adenocarcinoma, neuroblastoma, treatment sensitive and treatment-resistant glioblastoma (GBM), other cancers including breast cancer, renal cancer, lung cancer, ovarian cancer, esophageal cancer and pancreatic cancer, refractory hematologic malignancies, undifferentiated pleomorphic sarcoma, central nervous system tumors, prostate cancer, myxofibrosarcoma, ependymoma, angiosarcoma, rhabdomyosarcoma, spindle cell sarcoma, osteosarcoma, Ewing sarcoma, melanoma, pancreatic ductal adenocarcinoma, adult T-cell leukemia and lymphoma. The drug candidate is administered through intravenous route. The drug candidate is a small molecule and acts by targeting Glycogen synthase kinase-3 beta (GSK-3beta). It was also under development for the treatment of Alzheimer's disease and bladder cancer, Liposarcoma, soft tissue sarcoma, leiomyosarcoma, synovial sarcoma and bone sarcoma.
For a complete picture of Elraglusib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
